We recently published our article 5 Fast-Growing AI Healthcare Companies to Watch Right Now. To read the full article, head on to 10 Fast-Growing AI Healthcare Companies to Watch Right Now. In this piece, we take a closer look at RadNet Inc. (NASDAQ:RDNT) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.

Artificial intelligence is no longer limited to chatbots, digital advertising and Silicon Valley experiments. It is moving into hospitals, laboratories and pharmaceutical research, where algorithms are helping scientists discover potential medicines, interpret medical images, analyze genetic information and identify treatments suited to individual patients.

Interestingly, the termx term “artificial intelligence” was introduced in 1956, but medical AI took decades to become commercially practical. Modern healthcare systems now generate enormous amounts of clinical, imaging and genomic data—the exact type of information machine-learning models are designed to analyze.

Why Medicine Could Be AI’s Next Major Market

Drug development has traditionally required years of research, costly clinical trials and thousands of unsuccessful experiments. AI drug discovery platforms cannot eliminate those risks, but they can help researchers screen molecules, predict biological interactions and prioritize the most promising candidates before expensive trials begin.

Medical imaging has also become one of the earliest real-world applications of artificial intelligence in healthcare. AI-powered diagnostics can assist doctors in detecting abnormalities, improving image quality and prioritizing urgent cases. Meanwhile, precision medicine platforms are using clinical and genomic data to help match patients with more appropriate treatments.

These developments have encouraged investors to search for the best AI healthcare stocks, AI biotech stocks and medical AI companies positioned to benefit from the industry’s long-term expansion.

A Low Share Price Does Not Always Mean Cheap

A stock trading below $10 may look affordable, but it can still be overvalued if the company generates little revenue, loses money and repeatedly issues new shares. On the other hand, a profitable healthcare technology company trading above $50 may be undervalued when its earnings, cash flow and competitive advantages support a higher valuation.

The most attractive cheap AI medicine stocks therefore combine genuine medical applications with reasonable valuations, sufficient cash reserves, improving financial performance and meaningful long-term growth opportunities.

Finding the Best AI Medicine Stocks

This ranking evaluates NYSE- and Nasdaq-listed companies based on their AI exposure, valuation, revenue growth, financial strength, clinical potential and competitive position. Higher-risk companies were penalized for heavy losses, shareholder dilution, limited cash runways and uncertain paths to profitability.

The countdown begins with the most speculative AI medicine stock at No. 10 and ends with the strongest overall risk-adjusted pick at No. 1. These companies operate across AI drug discovery, precision medicine, genomic analysis, medical imaging, digital health and clinical research—some of the most promising fields where artificial intelligence could reshape modern healthcare.

CHECK THIS OUT: Top 10 Healthcare Stocks to Buy With $1000 in 2026 and 10 Best Medicine Stocks That Could Make Investors 100% Richer.

Our Methodology

For the 10 Cheap AI Medicine Stocks That Could Make You a Millionaire, we ranked each company based on its valuation, medical AI exposure, revenue growth, financial strength, clinical potential and overall investment risk.

5 Best Cheap AI Medicine Stocks to Buy Now

5. RadNet Inc. (NASDAQ:RDNT)

RadNet, Inc. (NASDAQ: RDNT) enters the top five by combining an extensive outpatient diagnostic-imaging network with one of the fastest-growing radiology AI businesses in the public market.

The company operates hundreds of imaging centers while developing artificial intelligence and digital-health products through its DeepHealth division. That structure gives it a major real-world advantage over software developers without their own clinical operations.

New AI tools can be tested and deployed inside an existing imaging network before being marketed to hospitals, radiology groups and healthcare systems. The company can also collect practical feedback from clinicians and incorporate it into future software development.

Second-quarter 2026 revenue increased 25% to a record $622.7 million. Adjusted EBITDA climbed 22.7% to approximately $99.7 million.

The Digital Health segment delivered even faster growth. Revenue increased 56.5% to $32.4 million, supported by rising adoption of the company’s AI products and digital-health services.

Its artificial intelligence portfolio can assist with cancer detection, image interpretation, clinical reporting and workflow management. These products address a genuine healthcare problem: medical-imaging volumes are increasing while many markets continue to experience shortages of trained radiologists.

The main limitation is that Digital Health still represents a relatively small portion of total company revenue. The segment also reported lower adjusted EBITDA during the quarter as management invested in sales, marketing, implementation and customer-service teams.

RadNet, Inc. (NASDAQ: RDNT) ranks fifth because it offers a sensible balance between established operations and emerging AI growth. Investors are not relying entirely on an experimental technology, but they still receive exposure to a digital-health division growing considerably faster than the broader company.

If DeepHealth becomes a larger part of the revenue mix, the market may increasingly value the business as an AI-enabled healthcare platform rather than only an operator of diagnostic-imaging centers.

YOU MUST READ THIS: Top 10 Healthcare Stocks to Buy With $1000 in 2026

Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.